Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Calcium & Vitamin D: Bone Mineral Density - Nutraceuticals World

What are you searching for?

Sign in
Research

Calcium & Vitamin D: Bone Mineral Density

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Nutraceuticals: Calcium & Vitamin D

Indication: Bone Mineral Density

Source: Epilepsia, 54(11):1997–2004, 2013

Research: Antiepileptic drug and osteoporosis prevention trial (ADOPT) was designed as a prospective 2-year double-blind, randomized placebo-controlled study involving 80 male veterans with epilepsy who were being treated with antiepileptic drugs (AEDs) such as phenytoin, phenobarbital, sodium valproate, or carbamazepine for a minimum of 2 years. All enrolled participants received calcium and vitamin D supplementation, and were randomized to risedronate or matching placebo. Total body, bilateral proximal femora and anteroposterior (AP) lumbar spine BMDs in addition to morphometric lateral vertebral assessments (LVAs) were evaluated by a dual energy x-ray absorptiometry (DXA) instrument. Comparisons of BMDs were made between baseline, 1 year and after 2 years of enrollment in the study. The incidence of new vertebral and nonvertebral fractures was the secondary end point.
Results: Of the 80 patients initially enrolled, 53 completed the study. At the end of the study, in the placebo plus calcium and vitamin D group, researchers observed a significant improvement in BMD at any of the evaluated sites when compared to their baseline scans in 69% (18/26). In the risedronate plus calcium and vitamin D group, researchers observed significant improvement of BMDs in 70% (19/27) of the participants. At the end of the study, the risedronate group experienced a significant increase of BMD at the lumbar spine, which was significantly larger than that seen in the placebo group. There were non-significant differences between the groups regarding changes of total body BMD or at the proximal bilateral femora.

Calcium and vitamin D together or in addition to risedronate improved BMD in more than 69% of male veterans with epilepsy who were taking AEDs. In the group receiving risedronate plus calcium and vitamin D there was a significant improvement of BMD at the lumbar spine as compared to the placebo group. The use of risedronate plus calcium and vitamin D prevented the incidence of new vertebral fractures and one nonvertebral fracture in this cohort.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics